The government has approved Merck's Molnupiravir, a new COVID-19 antiviral pill, for emergency use. Nimish Mehta, Founder and Director at Research Delta Advisors assessed its impact on the Indian companies
#OnCNBCTV18 | Nimish Mehta, Research Delta Advisors says not negative on #AurobindoPharma; Sandoz's dermatology & oral solids biz acquisition to help propel Auro’s US biz
Nimish Mehta To @BTVI : #Sandoz Deal Is A Good For Aurobindo Given $900 Mn Of Sales Post Buyout
The government has approved Merck's Molnupiravir, a new COVID-19 antiviral pill, for emergency use. Nimish Mehta, Founder and Director at Research Delta Advisors assessed its impact on the Indian companies.
Nimish Mehta Of Research Delta Shares His Views On Lupin | Halftime Report | CNBC TV18
Nifty Pharma Index Has Corrected Sharply, Nimish Mehta Shares His Views | Halftime Report